CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for NextGen Group plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

NextGen Group plc
8th floor, Kildare House, 3 Dorset Rise
Phone: 44 1480410850p:44 1480410850 London, EC4Y 8EN  United Kingdom Fax: 44 1480410858f:44 1480410858
This company is no longer actively traded on any major stock exchange.
Business Summary
NextGen Group Plc (NextGen) is engaged in the research and development services in the Biomarker arena for use within life science companies and academic institutions. The Company’s Biomarker service includes Biomarker Discovery, Biomarker Assay Development and Biomarker Testing. The Company’s subsidiaries includes NextGen Sciences Ltd., NextGen Sciences Dx Inc. and NextGen Sciences Inc. The Company’s subsidiary NextGen Sciences Inc. is engaged in the sales and service of products within biomarker discovery, development and testing. The Company’s subsidiary NextGen Sciences Dx Inc. offers researchers across pharma, biotech and clinical/translational settings. On February 22, 2012, the Company completed the establishment a diagnostics subsidiary NextGen Sciences Dx Inc.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/201112/31/2011Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Interim Chairman of the Board, Chief Financial Officer Leif S.Hamoe 8/10/2012 8/1/2009
Chief Marketing and Sales Officer, Executive Director Barry E.McAleer 8/1/2010 8/1/2010
Company Secretary AndrewWoods 1/1/2011 1/1/2011
Non-Executive Director ThomasBorcholte 56 7/11/2007 7/11/2007

Business Names
Business Name
NextGen Group plc
NGG
Proteomic Research Services Inc.

General Information
Outstanding Shares: 14,493,578 (As of 5/1/2012)
Stock Exchange: SEA
Fax Number: 44 1480410858
Email Address: info@nextgensciences.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023